

Close to Home

Message from the Board of Directors	2
Message from the Director	3
Patient Care	4
Research	12
Education	18
Network and Community	24
The Cancer Centers	32
Statistical Profile	34
Board Listing	36

The Cancer Institute of New Jersey at Cooper is an affiliate of The Cancer Institute of New Jersey, one of 39 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers nationwide. Our mission is to improve the prevention, detection, treatment and care of patients with cancer in South Jersey.

People facing cancer need to focus on fighting their cancer without the distraction of traveling for treatment. They need innovative care that’s close to home.

The Cancer Institute of New Jersey at Cooper provides comprehensive, multidisciplinary and innovative care—right in South Jersey. We combine patient-focused care and access to the latest cancer treatments and approaches available. Our extensive network means that cancer services are available throughout South Jersey, including in Voorhees, Stratford, Willingboro and Camden.

The Cancer Institute of New Jersey at Cooper—providing innovative cancer care to the people of South Jersey—close to home.

Message from the Board of Directors

The cancer rate in South Jersey has exploded. Over the last four years, there have been enough new cancer cases to fill Lincoln Financial Field. The need of the people of South Jersey for the best possible cancer care—and to have that care available close to home—has never been greater.

The Cancer Institute of New Jersey at Cooper, under the leadership of Generosa Grana, MD, FACP, provides comprehensive, multidisciplinary and innovative cancer care in South Jersey. We celebrate Dr. Grana's appointment as director. After an exhaustive national search, we found the right person to lead The Cancer Institute of New Jersey at Cooper right here in our backyard.

Dr. Grana has been a major presence on the Cooper campus for more than 10 years. A board-certified medical oncologist, she is nationally and internationally recognized as an expert in the field of breast cancer and the genetic aspects of breast cancer. Dr. Grana was instrumental in the development of Cooper's Breast Cancer Center, one of the first multidisciplinary cancer programs in the region and the model for all of Cooper's tumor site-specific programs. She also established the Cancer Genetics Program, the leading provider of cancer genetic testing and counseling services in South Jersey and the Dr. Diane Barton Complementary Medicine Program.

Dr. Grana's commitment to and compassion for her patients is unwavering. Within the community, she has spearheaded efforts to reach and educate minority communities about cancer prevention and screening, and to provide free screening and other services.

Research has played an important role in Dr. Grana's career. She has focused her efforts on the prevention of breast cancer through genetics and improving cancer treatments through clinical trials. Dr. Grana has participated in landmark clinical trials, including the recent NCI-sponsored Herceptin® (trastuzumab) studies in patients with HER2-positive invasive breast cancer which showed significantly decreased risk for breast cancer recurrence for patients with early-stage breast cancer who received Herceptin and chemotherapy, as well as increased survival. She is co-principal investigator on the NCI's Collaborative Familial Breast Cancer Registry, a



George E. Norcross III

Christopher T. Olivia, MD

collaborative project with the Fox Chase Cancer Center and the Coriell Institute for Medical Research. Dr. Grana has made more than 32 national presentations, co-authored 13 publications and presented 19 abstracts.

Dr. Grana earned her medical degree from Northwestern University School of Medicine and completed her residency in internal medicine at Temple University. She completed a fellowship in hematology and oncology at the Fox Chase Cancer Center and Temple University and a post-doctoral fellowship in preventive oncology at the Fox Chase Cancer Center.

Under Dr. Grana's expert guidance, The Cancer Institute of New Jersey at Cooper will flourish and become a model for the next generation in cancer care.

Sincerely,

George E. Norcross III
Chairman
Board of Trustees
Cooper University Hospital

Christopher T. Olivia, MD
President and CEO
Cooper University Hospital

Message from the Director

Cancer is a real burden to families in our community. I am honored to have been able to touch the lives of so many patients in South Jersey over the past decade.

The Cancer Institute of New Jersey at Cooper, an affiliate of the Cancer Institute of New Jersey, an NCI-designated Comprehensive Cancer Center, is spearheading the development of innovative cancer services in South Jersey. With an emphasis on patient care, research, education and community outreach, we have gathered a group of clinicians and researchers whose mission is to lead the fight against this major health threat.

In 2005, The Cancer Institute of New Jersey at Cooper expanded clinical care, research and outreach to bring the best care possible to cancer patients and their families. In clinical care, we established a new multidisciplinary cancer center: the Gastrointestinal Cancer Center. Together with the breast, genitourinary, gynecologic, leukemia and lymphoma, and lung cancer centers, we now cover the major cancer threats in South Jersey. We also recruited new medical staff within these existing centers.

Investments in innovative technology to help patients fight their cancer in 2005 include the minimally invasive superDimension™/Bronchus system, which enables our pulmonologists to diagnose lung cancer earlier and more accurately, and stereotactic body radiosurgery, which enables radiation oncologists to precisely deliver high-dose radiation intended to eradicate tumors in the abdominal, thoracic and pelvic regions while minimizing damage to normal tissues. We are helping cancer patients and their caregivers improve their emotional and spiritual well-being through the new Dr. Diane Barton Complementary Medicine Program, and manage cancer-related symptoms through our new Palliative Medicine and Behavioral Health Programs.

Cooper researchers took an active role in clinical and population research. They participated in over 100 clinical trials related to cancer prevention and treatment. Some of these studies, such as a study of partial breast irradiation compared to whole breast irradiation in early stage breast cancer, are available in South Jersey—and sometimes regionally—only at Cooper. A basic research program is under development.



Generosa Grana, MD, FACP

As the clinical campus of the University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School at Camden, we trained an excellent cadre of oncology fellows, residents and medical students. We also kept health care professionals up to date on cancer care through seven CME and two non-CME programs targeted to primary care providers and nurses in South Jersey.

In 2005, we expanded our network to include Brachfeld Medical Associates in Burlington County as well as continuing to expand services at the School of Osteopathic Medicine in Stratford, NJ. In the community, we provided free screening for breast and cervical cancer to approximately 1,000 women, sponsored hundreds of community programs and participated in the development and implementation of the New Jersey Comprehensive Cancer Control Plan.

Moving into the future, The Cancer Institute of New Jersey at Cooper will continue to launch new programs in clinical care, research and education, and to expand our network. We are committed to the prevention and treatment of cancer in a patient-focused setting within their own community.

Sincerely yours,

Generosa Grana, MD, FACP
Director, The Cancer Institute of New Jersey at Cooper
Associate Professor of Medicine, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School



Patient Care

Providing excellence in cancer care through a multidisciplinary approach, innovative technology and treatments, and a focus on patients

“The treatment of cancer is now truly multidisciplinary—a team of physicians working together to diagnose, assess and treat cancer improves patient outcomes.”

James Stevenson, MD
Medical Oncologist and Co-Director, Lung Cancer Center

Through six tumor site-specific centers, medical oncologists, radiation oncologists, surgeons, gynecologic oncologists and other specialists at The Cancer Institute of New Jersey at Cooper work together to provide optimal, individualized patient care. These centers cover the six largest cancer threats in South Jersey: breast, gastrointestinal, genitourinary, gynecologic, leukemia and lymphoma, and lung cancer. The Gastrointestinal Cancer Center was established in 2005. The Cancer Institute of New Jersey at Cooper also has a pediatric oncology program.

The recruitment of additional physicians enables the multidisciplinary centers to serve more patients and to provide a broader spectrum of services. Cooper recently welcomed:

- Francisca R. Fasipe, MD, Pediatric Hematology/Oncology
- Meenakshi Goyal-Khemka, MD, Pediatric Hematology/Oncology
- Erin O’Hea, PhD, Behavioral Medicine
- Raul O. Parra, MD, Urologic Surgery
- Eve Rodler, MD, Hematology/Oncology
- James Stevenson, MD, Hematology/Oncology
- Christopher J. Salgado, MD, Plastic Surgery
- Arthur Howard Siegel, MD, Palliative Medicine

The Cancer Institute of New Jersey at Cooper continually employs innovative technology and treatments to help patients fight their cancer. Innovations in 2005 include the superDimension™/Bronchus system and stereotactic body radiosurgery. Cooper is one of five centers in the United States and the only center in the region using the minimally invasive superDimension system to diagnose lung cancer earlier and more accurately. The system extends the reach of the bronchoscope to the lungs’ periphery, where the majority of lung lesions are located.

Stereotactic body radiosurgery enables radiation oncologists to precisely deliver high-dose radiation intended to eradicate tumors in the abdominal, thoracic and pelvic regions while minimizing damage to normal tissues. The technology, available in South Jersey only at Cooper, uses many pinpoint beams of high-dose radiation to ablate tumors.

Cooper physicians also innovate with existing technology and treatments. For example, in 2005, surgeons began using the da Vinci® Surgical System to perform robotic-assisted radical cystectomy and partial nephrectomies, as well as prostatectomy. Cooper is the only center in South Jersey and one of just three in the Delaware Valley that has the da Vinci surgical robot.

Excellence in cancer care goes beyond meeting the physical needs of patients. Cooper physicians provide support as well as clinical care, partnering with patients in their treatment. A nurse coordinator within each center supports, educates and assists patients and their families, serving as a link to their physicians and to supportive services. >>>

“With the superDimension™/Bronchus system, the work-up for lung cancer is safer and more effective, and leads to earlier, more accurate diagnosis.”

Melvin R. Pratter, MD
Co-Director, Lung Cancer Center



Members of Cooper’s lung cancer team with the superDimension/Bronchus system. From left to right: James Stevenson, MD, and Melvin R. Pratter, MD., Co-Directors of the Lung Cancer Center; and Pulmonologist Thaddeus C. Bartter, MD.

“Complementary medicine promotes wellness and healing, and helps improve the emotional and spiritual well-being of cancer patients and their caregivers.”

Bonnie Mehr
Director, Dr. Diane Barton Complementary Medicine Program

Comprehensive patient support services focus on meeting the emotional and practical needs of cancer patients. The Cancer Institute of New Jersey at Cooper offers personal and nutritional counseling, support groups, complementary medicine, physical therapy, risk assessment, genetic testing and counseling, social work services, and palliative care. Complementary medicine and palliative care were launched in 2005. The Behavioral Medicine Program began providing counseling and smoking cessation programs in 2005.

The Dr. Diane Barton Complementary Medicine Program integrates mainstream cancer therapy with complementary medicine. It includes: classes; a Live, Lunch and Learn lecture series; and one-on-one services such as acupuncture, massage and reflexology. Classes focus on relaxation/stress management therapies (e.g., mindful meditation), movement/mind-body therapies (e.g., yoga, Qi Gong) and expressive arts therapies (e.g., music therapy). >>>

Steven J. DiBiase, MD, Chief of the Department of Radiation Oncology, and Samuel L. Hughes, MD, a radiation oncologist, prepare a patient for treatment.



“It was someplace I could go to be among people who were going through what I was going through. It was always an uplifting experience.”

Julie Hanson
Patient

PATIENT PROFILE



Natalia Wilson-Reyes Cares for Baby While Battling Cancer

When Natalia Wilson-Reyes found a thumbnail-sized lump in her left breast, she was 35 years old and seven months pregnant with her first child. Two weeks after Natalia and her husband William welcomed their daughter Naysa, Natalia was diagnosed with an aggressive form of breast cancer. “It was devastating,” said Natalia, who lives in Eastampton, N.J. “I thought, ‘How can there be a God that would let me give life and make me face death at the same time?’”

Natalia was very motivated to keep her breast, so her multidisciplinary team of physicians at The Cancer Institute of New Jersey at Cooper recommended an alternative to mastectomy supported by research: chemotherapy before surgery to shrink the tumor. Since Natalia and William wanted to have more children and chemotherapy can impair fertility, the team recommended hormonal therapy along with her chemotherapy to help protect Natalia’s ovaries.

In six months, Natalia’s tumor had virtually disappeared. She then underwent a partial mastectomy with lymph node sampling followed by radiation therapy. Throughout her cancer treatment, Natalia continued to care for Naysa.

In May 2004, one year after completing her treatment for breast cancer, Natalia gave birth to her second child, a healthy baby boy, Zephan. Natalia has embraced both motherhood and surviving cancer. “Seeing my children wake up happy and smiling every day has definitely changed me. But the cancer has changed me too. Like my children, it has taught me to have a brighter outlook,” said Natalia.

“Being diagnosed with cancer is a very lonely feeling. We support our patients throughout their diagnosis and treatment, making navigating the system as smooth, easy and fast as possible.”

Ann Steffney, RN, MSN, OCN
Oncology Nurse Coordinator
Breast Cancer Center

PATIENT PROFILE



Complementary Medicine Helps Julie Hanson Cope with Breast Cancer

When Juliann (Julie) Hanson was diagnosed with stage IIIA breast cancer in her left breast at the age of 39, she coped by surrounding herself with positive things. Julie found many of those positive things at The Cancer Institute of New Jersey at Cooper’s complementary medicine and supportive care programs.

The middle school teacher at C.W. Lewis Middle School in Blackwood, N.J., had a mastectomy in November 2004, followed by chemotherapy and radiation therapy. As Julie was healing, she wanted to get out of the house, but didn’t feel up to doing much. She went to a Live, Lunch and Learn seminar, part of the Dr. Diane Barton Complementary Medicine Program. “I originally went because there was lunch,” quips Julie, who lives in Somerdale, N.J. Once there, however, Julie found comfort as well as knowledge at the monthly programs. “It was a place I could go to be among people who were going through what I was going through. It was always an uplifting experience.”

Julie attended other complementary medicine and supportive care programs at Cooper, including a health fair where she tried massage and Reiki (a Japanese technique for stress reduction and relaxation that also promotes healing). Through an American Cancer Society Look Good, Feel Better program held at Cooper, she learned beauty techniques to look good and feel better during chemotherapy and radiation therapy.

“Cooper provides a lot of services beyond the medical services,” said Julie. “They really help you get through an emotionally and spiritually trying time. Because of these services, I was able to keep a positive and happy attitude.”

PATIENT CARE

“Through palliative care, we can improve the lives of cancer patients and their families, and effectively control most cancer pain.”

Arthur Howard Siegel, MD
Director, Palliative Medicine Program

Palliative care helps cancer patients—from diagnosis to survival or the end of life—control their symptoms physically, socially, psychologically and spiritually. Arthur Howard Siegel, MD, joined Cooper in 2005 to head up the Palliative Medicine Program. Dr. Siegel recently completed a fellowship in palliative medicine at San Diego Hospice & Palliative Care, which is affiliated with the University of California, San Diego.

The only outpatient palliative care program in the region, the Palliative Medicine Program helps patients manage pain, depression and anxiety, nausea, fatigue, constipation, and other cancer-related symptoms and issues. Services include medication management, complementary medicine, physical interventions, behavioral interventions, psychological support, support groups and spiritual counseling.



Music therapy is part of the Dr. Diane Barton Complementary Medicine Program at Cooper.

“There are so many psychological and social difficulties in being diagnosed with cancer. We provide psychological resources to help people make sense of what’s going on, cope and feel like they’re not alone.”

Erin O’Hea, PhD
Director, Behavioral Medicine Program

PATIENT PROFILE



James Trout Conquers Heart Disease and Lymphoma

James Trout woke up after a triple bypass feeling great—until he learned that the surgeon hadn’t operated because the chest x-ray taken just before the procedure showed a mass on his lung. After the 59-year-old Maple Shade, N.J. man underwent bronchoscopy, a biopsy and a procedure to drain fluid around his lung, physicians diagnosed him with BALT (bronchial associated lymphoid tissue), a type of non-Hodgkin’s lymphoma.

“In a card game, some people get the good hands and some don’t. Having lymphoma and not lung cancer was like

getting a pretty good hand,” said James, who is a tool and die repairman for Electro Magnetic Products, a tool and die shop in Moorestown, N.J. Like all good card players, James played the hand he was dealt, stoically accepting his diagnosis.

James’ treatment plan called for chemotherapy (with Fludara®) followed by immunotherapy (with Rituxan®). Before starting chemotherapy, however, James’ heart needed to be stronger and he underwent angioplasty with stenting. The procedure was a success, and he began chemotherapy in April 2004, followed by immunotherapy in February 2005.

More than two years after first being diagnosed with both heart disease and lymphoma, James is doing great. The blockages in his coronary arteries are gone and his lymphoma is in remission.

“I was fortunate,” said James. “What I had wasn’t too bad. There were people who were worse off than me. Plus, everything worked well for me.”

PATIENT PROFILE

Maryann Thomas Enjoys a Second Chance After Beating Ovarian Cancer

Maryann Thomas watched her mother-in-law battle ovarian cancer for four years before the disease took her life. So when Maryann was diagnosed with ovarian cancer at the age of 37, she and her husband Bob were terrified.

Maryann knew that something was wrong when her periods began coming too close together, accompanied by a vague sense of discomfort. After an ovarian ultrasound revealed a mass, her gynecologist sent her to The Cancer Institute of New Jersey at Cooper.

Maryann needed surgery. During the procedure, her surgeon found a tumor the size of a man’s fist and had to remove both of Maryann’s ovaries and her fallopian tubes. Fortunately, the cancer hadn’t spread to the surrounding tissue, and Maryann’s cancer was classified as stage 1C.

“I felt so lucky when I found out what my staging was. It was like a second chance at life,” said Maryann, who owns Studio 561, a hair salon in Cherry Hill, N.J.

During her first cycle of chemotherapy, Maryann lost her hair. Despite being a stylist, she took it in stride. “I got a great wig. I got more compliments on my wig than I ever got on my hair.” Maryann went to work at the salon every day except for treatment days.

Having cancer has changed Maryann’s perspective on life. “I used to be so afraid of even saying the word ‘cancer.’ I now realize that it’s a part of life, and that there is life after cancer,” she said.

Cancer patients have access to individual therapy on coping with cancer through the Behavioral Medicine Program. Licensed psychologists and clinical psychology doctoral students provide the counseling. The program also focuses on prevention of cancer by changing cancer-causing behaviors, such as smoking. A six-week, research-based smoking cessation program was started in 2005 ■



Research

Accelerating the prevention, control, early detection and effective treatment of cancer through research

“It’s been proven that all patients at cancer programs offering clinical trials—not just those who participate in the trials—have better outcomes than those at programs that do not offer clinical trials.”

Robert A. Somer, MD

Director, Hematology/Medical Oncology Clinical Trials Program

Active involvement in clinical and population research enables The Cancer Institute of New Jersey at Cooper to provide patients with access to the latest cancer treatments and approaches available, as well as fostering cancer prevention and control, early detection, and diagnosis. A basic research program is under development.

Clinical Research

Cancer patients at Cooper have access to an extensive array of clinical trials through The Cancer Institute of New Jersey, NCI cooperative groups and industry. The Cancer Institute of New Jersey at Cooper participates in clinical trials from many NCI-cooperative groups, such as the Cancer and Leukemia Group B, Community Clinical Oncology Program, Eastern Cooperative Oncology Group, Gynecologic Oncology Group and Radiation Therapy Oncology Group.

Cooper researchers participated in more than 100 phase II, III and IV clinical trials in virtually all types of cancer in 2005. As part of each patient’s treatment plan, physicians recommend appropriate research studies focused on the disease in question.

In April 2005, the NCI released early results from two large randomized clinical trials of Herceptin® (trastuzumab) in patients with HER2-positive invasive breast cancer. Patients with early-stage breast cancer who received Herceptin in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence compared with patients who received the same chemotherapy without trastuzumab. Survival from breast cancer also increased. The NCI notified oncologists that they should consider Herceptin for women with early stage breast cancer that is HER2-positive who would have met the enrollment criteria for these clinical trials. Cooper researchers participated in these landmark studies.



Robert A. Somer, MD, Director of Hematology/Medical Oncology Clinical Trials Coordinator, with Ann Steffney, MSN, Nurse Coordinator of Breast Cancer Program, and Lois Carr, Operations Manager.

Many research studies at The Cancer Institute of New Jersey at Cooper are only available in South Jersey—and sometimes in the Delaware Valley—at Cooper. For example, Cooper researchers are evaluating the effectiveness of partial breast irradiation compared to whole breast irradiation in providing equivalent local tumor control in the breast following lumpectomy for early stage breast cancer. The Cancer Institute of New Jersey at Cooper is one of two trial sites in New Jersey for this NCI-sponsored phase III study. >>>

“Clinical trials enable us to move promising new drugs from the lab to the clinic, test their effectiveness in treating a variety of cancers, and ultimately to establish the best of these drugs as part of the standard of care for the treatments of specific cancers.”

David P. Warshal, MD

Director, Gynecologic Cancer Center

Population Research

Through population research to increase understanding of the complex interactions of environment, genetics, behavior and socioeconomic circumstance, Cooper researchers are working to help control cancer. In 2005, the Oncology Outreach Program and the Behavioral Medicine Program began a Lost to Follow-up Study, funded by NJ CEED (New Jersey Cancer Education and Early Detection), which provides free breast, cervical, colorectal and prostate cancer outreach, education, and screening services to uninsured Camden County residents. Researchers are studying why some women who are screened and have an abnormal result refuse follow-up care. Cooper is the coordinating center for the study, which will be conducted at six other hospitals in South Jersey.

Behavioral medicine research focuses primarily on predictors of psycho-social distress in women with breast cancer. One study started in 2005 is following women from diagnosis to six months post-treatment to examine issues that provoke depression at different stages of disease. Results will be used to guide interventions at Cooper.

In a geriatric oncology study started in 2005, Cooper researchers seek to determine the effects of chemotherapy on the mental and physical condition of older patients. They are trying to determine whether chemotherapy’s effect on cognitive and physical functioning varies depending on age. The New Jersey State Legislature is funding the study, which is a collaboration between Cooper, the University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, and the New Jersey Institute for Successful Aging.

The Cancer Institute of New Jersey at Cooper continued to collaborate with the Fox Chase Cancer Center and the Coriell Institute for Medical Research on the NCI’s Collaborative Familial Breast Cancer Registry. This registry provides an international research infrastructure for researchers interested in conducting population and clinic-based interdisciplinary studies on genetic and molecular epidemiology of breast and ovarian cancer and its behavioral implications. >>>

“Members of the study staff were very supportive and accommodating. They listened to my worries and answered all of my questions. They also guided me in things that weren’t related to the study.”

Deborah RoyRoberts

Patient

PATIENT PROFILE



Deborah RoyRoberts Participates in Landmark Herceptin Study

Like many people, Deborah RoyRoberts never thought that she would participate in a clinical trial. “I thought it was a risk,” said the 49-year-old homemaker from Malaga, N.J. Today, Deborah feels that she is fortunate to have participated in an NCI-sponsored study of Herceptin® in early stage HER2-positive breast cancer at The Cancer Institute of New Jersey at Cooper. The study that Deborah participated in was one of two Herceptin trials in early stage HER2-positive breast cancer.

After a mastectomy revealed that Deborah’s cancer was HER2-positive, her oncologist recommended the Herceptin study in combination with conventional chemotherapy as part of Deborah’s treatment plan. “Participating in a clinical trial gave me absolutely the best level of care,” said Deborah. “Members of the study staff were very supportive and accommodating. They listened to my worries and answered all of my questions. They also guided me in things that weren’t related to the study.”

Deborah’s perceptions about clinical trials have changed dramatically. “I feel good and I look good. I feel very fortunate that I was able to participate in this trial,” she said.

RESEARCH

“With today’s technology, the opportunities to use basic research to develop new approaches to the diagnosis and treatment of disease are unprecedented.”

Peter W. Melera, PhD

Associate Dean for Research, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School-Camden

Associate Director for Basic Research, The Cancer Institute of New Jersey at Cooper

Basic Research

The Cancer Institute of New Jersey at Cooper will play a major role in the establishment of an interdisciplinary, collaborative basic research program in Camden that is under development. In 2005, Peter W. Melera, PhD, joined the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School to assist in the program’s design and implementation. This effort at the Robert Wood Johnson Medical School is intended to foster translational research, and, with strong support from

CINJ at Cooper, will initially focus on cancer, including lung, breast, prostate and hematologic malignancies. It will leverage all of the research resources available in Camden—the Robert Wood Johnson Medical School, Cooper University Hospital, CINJ at Cooper, the Coriell Institute for Medical Research, and Rutgers University—to accomplish its goal.

Faculty of CINJ at Cooper have worked collaboratively with researchers at Coriell Institute to spearhead the development of research programs in breast and prostate cancer as well as to develop a coed program that will serve as NIDUS for stem cell research on the Camden campus ■

Faculty of CINJ at Cooper have worked in collaboration with researchers at the Coriell Institute. Shown is a cryogenic storage facility at the Coriell Institute.



Dana Farengo Clark, MS, is a certified genetic counselor at the Cancer Genetics Program, Cancer Institute of New Jersey at Cooper in Voorhees.



PATIENT PROFILE



Frank Zimone Finds Aggressive Treatment for Prostate Cancer

As president and CEO of Denton Vacuum, a high-tech company headquartered in Moorestown, N.J., Frank Zimone is used to being proactive and analyzing situations objectively. So when Frank was diagnosed with high-risk prostate cancer at the age of 47, he spent weeks learning about the disease. “The more I read, the more I learned that there’s no one way to address this disease. I realized that I had to play a significant role in choosing the right treatment option for me,” he said.


Frank’s primary care physician, Frank Pettinelli, MD, referred him to The Cancer Institute of New Jersey at Cooper, where Steven J. DiBiase, MD, Chief of the Department of Radiation Oncology, recommended a clinical trial that combined external

radiation, hormone therapy, chemotherapy and radioactive seed implantation (brachytherapy). Cooper is the only medical center in the country offering this study. As of December 2005, more than 40 men had participated in the study, with very encouraging results.

“Personally and professionally, I found this aggressive approach very appealing. It was difficult for me to see any possible downside to participating in this clinical trial,” said Frank.

Participating in a clinical trial was a “fantastic experience” for Frank. “All members of the Cooper team were singularly focused on me as a patient. It was very comforting to know that this team was going to worry about me and take care of me while I went through what for me was the uncharted waters of prostate cancer,” he said.

Frank received most of his treatment at Cooper’s Voorhees facility, just a few minutes from his home in Cherry Hill, N.J. “I could have gone anywhere on the planet for care and would have, with no concerns for finances or logistics. To come to the conclusion that I only had to go 500 yards for the best care available was pretty amazing,” he said.



Education

Training the next generation of physicians and keeping health care providers abreast of innovations in oncology

“Training the next generation of physicians keeps us up to speed. In order to teach, we must have in-depth knowledge about innovations in oncology.”

Alexandre Hageboutros, MD

Director, Hematology/Medical Oncology Fellowship Program
Associate Professor of Medicine, University of Medicine and Dentistry of New Jersey,
Robert Wood Johnson Medical School

Faculty members within The Cancer Institute of New Jersey at Cooper play a leading role in training medical students, interns, residents and fellows, as well as keeping health care professionals updated on advances in cancer treatment and research. Cooper is a clinical and core teaching campus for the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School-Camden, which serves third and fourth year medical students. The Robert Wood Johnson Medical School-Camden—one of 56 clinical campuses nationwide—was recently designated a model clinical campus by the American Association of Medical Colleges. Faculty members in the Division of Hematology/Oncology also develop and teach the hematology/oncology curriculum at the four-year University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine.

Alexandre Hageboutros, MD, Director, Gastrointestinal Cancer Program, consults with colleagues



Cooper had five hematology/medical oncology fellows in 2005. The fellowship program lasts three years, with up to two new fellows starting each year. All internal medicine residents rotate through oncology in their first year and can take an optional oncology rotation in their second year. Medical students at the Robert Wood Johnson Medical School-Camden and the School of Osteopathic Medicine attend lectures by Cooper faculty.

Outside the classroom, medical students, interns, residents and fellows get hands-on training through rounds and grand rounds. Fellows and residents also attend the multidisciplinary tumor board, where they observe medical oncologists, radiation oncologists, surgeons, and other specialists discuss cases and develop and implement treatment plans. Faculty members present a lecture series for fellows and collaborate with them on research projects. >>>

FELLOW PROFILE

Fellow Shoba Kankipati, MD, Thrives on Change

The dynamic nature of oncology would deter many physicians from pursuing a career in the specialty. For Shoba Kankipati, MD, one of five hematology/oncology fellows at The Cancer Institute of New Jersey at Cooper, it's what she likes best about her work.

“Oncology has come a long way and it keeps changing,” said Dr. Kankipati, who grew up in Pakistan. “New ideas continue to evolve. That keeps me sharp.”

Dr. Kankipati earned her medical degree at St. George's University School of Medicine in Grenada for two years and did her clinicals and post-graduate training in the United States. During her residency at Drexel University College of Medicine, she received an Outstanding Patient Care Award and an Outstanding Graduating Resident Award. Dr. Kankipati began her three-year Cooper fellowship in 2003, the same year she gave birth to her first child, Anjali.

As a Cooper fellow, Dr. Kankipati is gaining the knowledge and support she needs to thrive as an oncologist. “The faculty members at Cooper are great mentors, and they're very approachable. I've learned tremendously from them,” she said.

The fellowship program combines clinical care, education and research. A poster on ductal carcinoma in situ in patients with BRCA mutations that Dr. Kankipati developed in collaboration with Cooper faculty and other fellows was selected for discussion at the 2005 San Antonio Breast Symposium. Dr. Kankipati also collaborated on a poster on off-pump bypass surgery for cold agglutinin disease that won second prize at the 2004 Annual GMC Resident/Fellow Research Poster Competition.

Although she enjoys research, Dr. Kankipati defines herself primarily as a clinician. When Dr. Kankipati completes her fellowship in June 2006, she plans to find a position where she can devote the majority of her time to patient care.

FELLOW PROFILE



Fellow Maroun Edmond El-Khoury, MD, Provides Patient-Focused Care

For Maroun Edmond El-Khoury, MD, caring for cancer patients means focusing on their needs. “We should do more than just treat their malignancy. We should address their social and psychological issues, and be able to maintain a balance between their hopes and the truth, their quality of life and cytotoxic chemotherapy with its complications,” said Dr. El-Khoury, one of five hematology/oncology fellows at The Cancer Institute of New Jersey at Cooper.

After earning his medical degree from the Saint Joseph University School of Medicine in Beirut, Lebanon, where he grew up, Dr. El-Khoury came to the U.S. for his postgraduate training. He completed a residency at the University of Kansas School of Medicine before starting his Cooper fellowship in 2003.

“When I started my fellowship, I was aware of the challenges in caring for cancer patients,” said Dr. El-Khoury. “At Cooper, I am getting the appropriate education and support to meet these challenges.”

Dr. El-Khoury has also participated in research related to hematologic malignancies and gastrointestinal cancers during his fellowship. In collaboration with Cooper faculty and other fellows, he co-authored three articles that were published in Breast Cancer Research and Treatment and Haemostasis and Thrombosis, and worked on poster presentations and abstracts presented at annual oncology meetings and Cooper research forums.

Dr. El-Khoury plans to join a private medical practice when he completes his fellowship in June 2006. “Hopefully, I will be able to apply the skills I learned from my outstanding mentors,” he said.

Faculty members keep physicians, nurses and other health care providers updated on advances in cancer treatment and research through CME programs, contact hour programs (for nurses) and other programs. In 2005, The Cancer Institute of New Jersey at Cooper sponsored seven CME programs, which drew 397 health care providers. Programs covered "Advancing Science through Clinical Research" and updates on gynecologic disease, breast cancer (two programs), lung cancer, prostate cancer and colorectal cancer.

The Cancer Institute of New Jersey at Cooper has an active nursing education program. In 2005, Cooper sponsored 30 contact hour and non-contact hour programs. Programs included Oncology Overview (a mandatory course for new staff) and Oncology Nursing Society Cancer Chemotherapy and Biotherapy Administration,

each of which are offered twice a year. In 2005, five Cooper nurses completed training as Oncology Nursing Society chemotherapy providers and now train other nurses in the Oncology Nursing Society Cancer Chemotherapy and Biotherapy Administration course.

Topics for other nursing education programs ranged from "Anemia in the Cancer Patient" to "Introduction to Monoclonal Antibodies." The monthly Oncology Nurses Night Out series included presentations on radiation oncology and prostate cancer in 2005. The 2005 annual Cutting Edge of Cancer Conference drew 116 nurses, social workers and other professionals who work with cancer patients from Cooper and throughout the Delaware Valley ■



Nurse coordinators Alice O'Brien, MSN, Hematologic Malignancies, Kay Hannigan, MSN, Gastrointestinal Oncology, and Charu Vora, MSN, Lung Oncology.

"Cancer care is constantly changing. Cooper's oncology nursing education programs enable our nurses to keep up with these changes."

Christina Hunter, RN, BSN, OCN
Oncology Clinical Educator



Chemotherapy laboratory at the Cancer Institute of New Jersey at Cooper-Voorhees



Network and Community

Extending comprehensive cancer care and research throughout South Jersey and supporting the community through cancer screening, education and control activities

A Network of Access Points

To provide excellence in cancer care, research and community programs close to home, The Cancer Institute of New Jersey at Cooper is building a local network throughout South Jersey. As part of The Cancer Institute of New Jersey, The Cancer Institute of New Jersey at Cooper brings the resources of a national network of NCI-designated Comprehensive Cancer Centers to this effort. The Cancer Institute of New Jersey is one of 39 Comprehensive Cancer Centers.

The Cancer Institute of New Jersey at Cooper provides services in Voorhees, Stratford, Camden and Willingboro:

- Voorhees: This spacious modern outpatient facility is at 900 Centennial Boulevard near Routes 295, 73 and 70.
- Camden: Camden is home to Cooper University Hospital, a 554-licensed bed, not-for-profit academic medical center that specializes in the treatment of seriously ill and critically injured patients. The hospital is near Routes 42/1-76 and 30.
- Stratford: Just off the White Horse Pike, the Stratford office is at the University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine.
- Willingboro: Located in Burlington County off of Route 130, this outpatient office provides access to several hematologists–oncologists, chemotherapy infusion, nurse coordinators and other cancer services.

PATIENT PROFILE



Reverend Harald Peeders Seeks NCI-Affiliated Cancer Center

For 33 years, Reverend Harald Peeders has been helping other people cope with life's crises, including being diagnosed with cancer. In February 2005, the 63-year-old Lutheran minister at Holy Trinity in Burlington, N.J. learned what it was like to be the one facing the crisis, when he was diagnosed with prostate cancer, with a PSA level of 9.9.

After coming to terms with his diagnosis, Reverend Peeders began researching prostate cancer and cancer care. "The National Cancer Institute kept popping up," said Reverend Peeders. "I began to realize that the National Cancer Institute was a nationwide umbrella under whose auspices the best hospitals provided care for cancer patients."

Reverend Peeders looked around for a local hospital that was affiliated with the National Cancer Institute (NCI)—and found The Cancer Institute of New Jersey at Cooper (part of The Cancer Institute of New Jersey, an NCI-designated Comprehensive Cancer Center). In June 2005, he and his wife Gay came to Cooper. They met with a radiation oncologist, a surgeon and a medical oncologist, who explained Reverend Peeders' treatment options, including robotic-assisted radical prostatectomy.

Impressed with the innovative technology demonstrated by the surgical robot and the good science behind it, Reverend Peeders chose robotic-assisted radical prostatectomy. After the procedure, performed on June 28, 2005, his PSA level was down to less than 0.1.

Today, Reverend Peeders is back to being the caregiver for the members of Holy Trinity. "Every day I wake up and am very thankful that I'm healthy and can go to work," he said. "I realize how fragile life is and try to be happy with the normal frustrations and joys of each day."

"Our affiliation with Cooper provides tremendous benefits to our patients. We are providing our patients with access to more subspecialists in oncology and other medical specialties, and can now deliver sophisticated chemotherapy at our infusion center."

Robert Calvo, MD

Hematologist, Cooper–Brachfeld Medical Associates



Members of Cooper's breast cancer team, one of several cancer-specific teams, are (front row, left to right): Eve Rodler, MD; Generosa Grana, MD, Director, Breast Cancer Center and Director of CINJ at Cooper. (Back row, left to right): Susan Hunter, RN, MSN, NPC, AOCN; Samuel Hughes, MD; Christopher Salgado, MD; Frank Koniges, MD; Robert A. Somer, MD; Ann Steffney, MD, MSN, OCN; and Umur Atabek, MD.

In 2005, The Cancer Institute of New Jersey at Cooper expanded its network to Burlington County, when Cooper University Hospital added the Brachfeld Medical Associates to its physician group practice. Based in Willingboro, N.J., Brachfeld Medical Associates has been providing patients with comprehensive, compassionate, state-of-the-art care for more than 35 years. A new office for cancer clinical services and clinical research will be opened near the existing Willingboro medical complex.

Research partnerships comprise another key part of the network. Researchers at The Cancer Institute of New Jersey at Cooper are members of many NCI cooperative groups and are also part of The Cancer Institute of New Jersey's research network. Major research partners include the Coriell Institute for Medical Research, the Fox Chase Cancer Center, and the University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine. >>>

Community

Within the South Jersey community, in 2005 The Cancer Institute of New Jersey at Cooper provided free cancer screening; sponsored educational, motivational and supportive community programs; participated in community events; and participated in county-wide and state-wide cancer control initiatives. Community programs and outreach activities are targeted toward underserved populations, as well as the larger community.

A component of Cooper's inpatient pediatric care is the Child Life Program with a focus on providing emotional, social, physical and cognitive growth for young patients.

Through the Camden County Cancer Screening Project, medical staff within the Oncology Outreach Program screened 982 women for breast cancer, 1007 women for cervical cancer, 93 men for prostate cancer, and 259 men and women for colorectal cancer. Funded by the New Jersey Cancer Education and Early Detection (NJCEED) program and the Centers for Disease Control and Prevention, this project provides free outreach, education and screening services to uninsured men and women in Camden County for breast, cervical, colorectal and prostate cancer.

Through the Camden County Cancer Screening Project, the Oncology Outreach Program also provides diagnostic testing for screening participants with abnormalities; one-on-one counseling and case management services; help with transportation; emotional support and follow-up post-diagnosis and treatment; and community education. In 2005, the program provided approximately 45 educational programs at churches, housing projects, schools and community organizations in Camden County. >>>



Christopher J. Salgado, MD, plastic surgeon, regularly treats individuals who are recovering from skin cancers, as well as women who have undergone mastectomies.



Steven Peiken, MD, Division Head of Gastroenterology, routinely screens patients for colorectal cancer.



PATIENT PROFILE



Elva Hopkins Receives Cancer Care Through Community Program

Elva Hopkins and her husband, Steven, had worked hard all their lives. Steven was a self-employed electrician, and Elva was a data entry operator who provided health insurance for the family through her job. Then the company Elva worked for declared bankruptcy in the fall of 2002, and the family no longer had health insurance. In March 2003, Steven died suddenly of heart disease at the age of 49.

When Elva found a lump on her right breast in May 2004 at the age of 53, she didn't know how she would get the care that she needed. "I was upset because my husband had passed

away and I was uninsured. I didn't know where to turn. I didn't know what to do," said the Pennsauken, N.J. resident.

Elva's sister Anna found the solution—the Camden County Cancer Screening Project, which provides free screening and other services to uninsured men and women in Camden County and is based out of The Cancer Institute of New Jersey at Cooper. Anna, who had health insurance, had been diagnosed with breast cancer a few months earlier and was a Cooper patient.

Through the Camden County Cancer Screening Project, Elva received testing, assistance with applying for Charity Care and Medicaid, and emotional support. After a biopsy showed that she had invasive ductal carcinoma in her right breast, Elva underwent a mastectomy, followed by chemotherapy, reconstructive surgery and Herceptin therapy. Medicaid paid for all of her treatment.

"I'm so thankful to all of the people at Cooper who helped me. Everyone was helpful and caring, especially the staff of the Camden County Cancer Screening Project," she said.

“As we go out into the community and become a part of it, we can find out what people need and create programs to meet those needs.”

Evelyn Robles-Rodriguez, RN, MSN, NPC, AOCN
Director, Oncology Outreach Program

Other oncology outreach activities in 2005 include a project to educate minority communities about clinical trials and a book to help minority women diagnosed with breast cancer decide which type of surgery to have. Under a grant from the New Jersey Commission on Cancer Research, Cooper is participating in IMPACT New Jersey (Improving Minority and Medically Underserved Participation & Access in Clinical Trials), a train-the-trainer program to educate community leaders and the people they recommend about clinical trials and debunk some of the myths around clinical trials.

In Unveiled, minority women with breast cancer share their stories and their post-surgical photos. The Central and South Jersey Affiliate of the Susan G. Komen Breast Cancer Foundation, NJ CEED, and a Cancer Institute of New Jersey Novartis Outreach Education grant fund this project.

Within the larger community, The Cancer Institute of New Jersey at Cooper sponsored 23 community programs in 2005 and participated in countless special events. Cooper physicians, nurses, and other medical and support staff are all involved in these programs and events. Community education programs in 2005 included “Caring for Yourself After Breast Cancer” and the six-week “Don’t Put it Off Any Longer...Quit Smoking Today” program. Motivational and supportive programs include the annual Celebration of Life and Remembrance, which celebrates the lives and accomplishments of cancer survivors and loved ones who died from the disease.

The Cancer Institute of New Jersey at Cooper participates in many special events, as a sponsor and through team and individual participation of staff. In 2005, Cooper established Laugh for Life, an annual fundraiser for the Dr. Diane Barton Complementary Medicine Program held at a local comedy club, and was the major sponsor for the 2nd Annual South Jersey Lung Cancer Walk/Run & Rally, started by Cooper lung cancer patient Heather Saler. Cooper also participates in events such as the American Cancer Society Relay for Life.

PATIENT PROFILE



Walking Toward a Cure for Lung Cancer

Heather Saler wants researchers to find a cure for lung cancer. The 36-year-old from Mt. Laurel, N.J., who was diagnosed with stage IIIA non-small cell lung cancer in February 2003, isn’t sitting around waiting. In 2004, she organized the 1st South Jersey Lung Cancer Walk/Run and Rally to raise awareness of lung cancer and money for research.

“I became very frustrated about the lack of funding for lung cancer, which is the number one cancer killer. I wanted researchers to find better treatments, if not a cure, and couldn’t

understand why the statistics have remained so bad,” said Heather, who never smoked.

The 2004 Walk/Run and Rally, held at Cooper River Park in November 2004, drew 350 participants and raised \$32,000 for lung cancer research. Heather donated the money to the LUNgevity Foundation, a group founded by lung cancer survivors to increase funding for lung cancer research. LUNgevity partners with the American Cancer Society, American Lung Association and others to make its research awards.

Heather organized the 2nd Annual South Jersey Lung Cancer Walk/Run and Rally held on November 5, 2005. Three hundred and fifty people participated, raising \$45,000. The Cancer Institute of New Jersey at Cooper was the major sponsor.

“Since being diagnosed with lung cancer, I appreciate every day that I have and try to make a difference,” said Heather. “I plan to continue organizing the Annual South Jersey Lung Cancer Walk/Run.”

“It’s clear that to have an impact on the morbidity and mortality of most of the common cancers, we have to attack the root cause and implement prevention measures. We have to move from diagnosis and treatment to prevention and early detection. Without a consortium of primary care providers and tertiary care facilities, we will not be able to make the progress we need to make in the 21st century.”

Arnold Baskies, MD

Chairman, Governor’s Task Force on Cancer Prevention, Early Detection, and Treatment (which was responsible for constructing the New Jersey Comprehensive Cancer Control Plan)
Assistant Clinical Professor of Surgery, Robert Wood Johnson Medical School




Frank DelRossi, CSW, meets with a patient to review available social services.

The Cancer Institute of New Jersey at Cooper is an active participant in the New Jersey Comprehensive Cancer Control Plan, which seeks to coordinate and integrate cancer control activities statewide and is administered by the New Jersey Department of Health and Senior Services. The plan focuses on—breast cancer, cervical cancer, colorectal cancer, lung cancer, melanoma, oral and oropharyngeal cancer, and prostate cancer—along with five overarching issues: access and resources, advocacy, childhood cancer, nutrition and physical activity, and palliation.

County-level coalitions will be implementing the plan. The Cancer Institute of New Jersey at Cooper is the lead agency for the Camden County Cancer Coalition, comprised of public and private agencies and health care providers. In 2005, the coalition established four work groups:

- Lung Cancer and Smoking Cessation, which will work with local schools
- Eliminating Health Disparities, which will use Cancer Information Services maps to identify groups of people and determine their needs
- Urban Health Initiatives, which will work with the American Cancer Society to determine the needs of Camden residents and develop programs to meet those needs
- Tri-County Health Initiatives, which will develop programs for Camden, Gloucester and Burlington counties ■

THE CANCER CENTERS




Breast Cancer



THE BREAST CANCER CENTER

The Breast Cancer Center offers in-depth assessment, screening and counseling for high-risk individuals. Stereotactic and ultrasound-guided biopsy procedures are available to help ensure the most precise diagnosis possible. In addition, Cooper actively participates in important research projects, including one to help decipher the hereditary components of breast cancer.

Lung Cancer



THE LUNG CANCER CENTER

Lung cancer continues to pose a significant health hazard to our population. The Lung Cancer Center brings a multidisciplinary team approach to the diagnosis and treatment of this disease. As a result, patients have access to an expert team of pulmonologists, medical oncologists, radiation oncologists, surgeons and oncology nurses.

Lymphoma and Leukemia



THE LYMPHOMA AND LEUKEMIA CENTER

The exceptional medical team associated with the Lymphoma and Leukemia Center includes surgeons, hematologic oncologists, radiologists, radiation oncologists and nuclear medicine specialists. Also included are experts in cytogenetics and magnetic resonance imaging. Treatment ranges from standard chemotherapy and radiotherapy to the use of newly developed antibodies and vaccines.


Gastrointestinal Cancer



THE GASTROINTESTINAL CANCER CENTER

The center's multidisciplinary staff includes general and colorectal surgeons, gastroenterologists, medical and radiation oncologists, and enterostomal therapy. This outstanding team meets regularly to discuss the needs of individual patients and share information about new advances in the treatment of conditions of the colon, rectum and anus.


Gynecologic Cancer



THE GYNECOLOGIC CANCER CENTER

This cancer center is the only comprehensive center of its kind in the region. It offers diagnosis and treatment of precancerous tumors and malignancies of the ovaries, uterus, vagina, vulva and the pregnant uterus. Cooper also has its own dedicated chemotherapy facility for women undergoing treatment for gynecologic cancer.

Genitourinary Cancer



THE GENITOURINARY CANCER CENTER

This center provides comprehensive screening, minimally invasive surgery and state-of-the-art treatment for malignancy of the prostate. Bladder, kidney, testicular and penile cancers are also treated. In addition, Cooper researchers are looking for ways to provide earlier diagnosis of prostate cancer and improved tumor-specific treatment.

THE CANCER GENETICS PROGRAM

The program identifies and assists individuals who may—because of family history—have a greater potential of contracting breast cancer, ovarian cancer, colon cancer or melanoma. Genetic testing is provided when appropriate. Specific recommendations and preventive approaches are also discussed. The staff includes a medical oncologist, nurse educator and genetic counselor.

THE DR. DIANE BARTON COMPLEMENTARY MEDICINE PROGRAM

This important program enhances the quality of life and wellness of individuals touched by cancer including caregivers and family members. It utilizes therapies that focus on mind, body and spirit. These complementary therapies are used in support of traditional medical care and are designed for the well-being of individuals confronting cancer.

STATISTICAL PROFILE

PATIENT CARE

Inpatient			2003	2005
Cases			942	1,292
Days			6,549	8,382
Average length of stay			6.95	6.49
Average length of stay for 90% of cases			4.47	4.18
		Outpatient		
Professional	2003	2005	2003	2005
Hematology/Medical Oncology				
New Visits	962	1,455	845	1,526
Follow-up Visits	10,273	14,030	3,075	4,180
Treatment	5,902	9,654	NA	NA
Radiation Oncology				
New Visits	385	532	96	145
Follow-up Visits	422	1,325	6	3
Treatment	11,796	12,115	NA	NA
Gynecologic Oncology				
New Visits	870	830	165	158
Follow-up Visits	3,542	3,962	401	526
Treatment	1,124	1,320	NA	NA
Surgery				
New Visits	646	984	132	172
Follow-up Visits	2,031	1,682	44	157
Camden County Screening Program				2005
Breast Screening				982
Cervical Screenings				1,007
Colorectal Screenings				259
Prostate Screening				93
Cancer Diagnosis				10
Cancer in Situ				7
Colonoscopies				58

RESEARCH

Clinical Trials Activity			2005	
	Open	Accrual		
Hematology/Medical Oncology				
NIH Sponsored	20			35
Industry Sponsored	31			24
Investigator Initiated	1			0
Gynecologic Oncology				
NIH Sponsored	39			14
Industry Sponsored	3			7
Investigator Initiated	0			0
Radiation Oncology				
NIH Sponsored	10			14
Industry Sponsored	2			2
Investigator Initiated	1			2
Clinical Research Awards				2005
NIH			\$	573,574
Industry			\$	693,897
Total			\$	1,267,471

PROGRAM/SERVICE AWARDS

	2005	
State Allocation	\$	9,000,000
Cancer Education and Early Detection Program	\$	412,500
Program	\$	120,657
Total	\$	9,533,157

NEW PATIENT COUNTY OF ORIGIN

	Hematology/Medical Oncology		Gynecologic Oncology		Radiation Oncology		All	
	2003	2005	2003	2005	2003	2005	2003	2005
Camden	48.07	45.96	18.95	20.53	59.22	53.39	39.06	40.29
Burlington	17.57	23.16	18.31	16.82	16.88	18.9	17.72	20.5
Gloucester	14.4	12.89	7.68	10.86	9.35	12.66	10.89	12.27
Atlantic	2.38	4.22	13.19	10.46	2.08	2.94	6.45	5.72
Cumberland	2.27	1.82	2.56	3.05	2.34	2.94	2.39	2.39
Salem	2.15	1.46	0.38	0.66	0.52	1.65	1.17	1.27
Cape May	1.13	1.68	1.92	1.59	1.04	0.73	1.42	1.46
Subtotal	87.97	91.19	62.99	63.97	91.43	93.21	79.10	83.90
Bucks	--	--	12.16	15.76	--	--	--	--
Mercer	--	--	5.89	4.64	--	--	--	--
Total	87.97	91.19	81.04	84.37	91.43	93.21	79.10	83.90

EXECUTIVE COMMITTEE

Generosa Grana, MD, Director, The Cancer Institute of New Jersey at Cooper University Hospital

Charles E. Sessa, Chairman of the Board, Cooper University Hospital

Christopher T. Olivia, MD, President and CEO, Cooper University Hospital

Stephen Rimar, MD, Executive Vice President and Chief Medical Officer, Cooper University Hospital

William N. Hait, MD, PhD, Director, The Cancer Institute of New Jersey

Harold L. Paz, MD, Dean, Robert Wood Johnson School of Medicine, UMDNJ

Michael R. Gallagher, DO, Dean, School of Osteopathic Medicine, UMDNJ

ADMINISTRATION

Generosa Grana, MD, Director, The Cancer Institute of New Jersey at Cooper

Rachelle Munic, MBA, PA-C
Assistant Vice President, Cancer Services

CLINICAL CARE**Behavioral Medicine**

Erin O’Hea, PhD

Dermatology

Warren Heymann, MD, Head
Steven Manders, MD
Justin Green, MD

Procedural Dermatology

Naomi Lawrence, MD, Director
Janie Leonhardt, MD

Gastroenterology

Steven R. Peikin, MD, Chief
Louis Chaptini, MD
Christopher W. Deitch, MD
Adam B. Elfant, MD
Jack Goldstein, MD
Tom Judge, MD
Cynthia McCleery, MD
Donald Petroski, MD
David Zisa, MD

Gynecologic Oncology

David P. Warshal, MD, Chief
Thomas F. Rocereto, MD
James K. Aikins Jr., MD

Hematology Oncology

Generosa Grana, MD, Head
Alexandre Hageboutros, MD,
Assistant Division Head
Linda Devereux, MD
Neil A. Lachant, MD

Kumar Rajagopalan, MD
Eve Rodler, MD
Robert A. Somer, MD
James P. Stevenson, MD

Palliative Medicine

Arthur Siegel, MD

Pathology

Edison Catalano, MD, Chief
Jeanette M. Camachio, MD
Bruce Kane, MD
Jun Liu, MD
William Rafferty, MD

Pediatric Hematology/Oncology

Francisca R. Fasipe, MD
Meenakshi Goyal-Khemka, MD

Pulmonary Medicine

Melvin R. Pratter, MD, Head
Stephen M. Akers, MD
Thaddeus C. Bartter, MD
Jonathan E. Kass, MD
Ramya Lotano, MD

Radiation Oncology

Steven J. DiBiase, MD, Chief
Clarisa Henson, MD
Samuel L. Hughes, MD

Radiology

Raymond L. Baraldi Jr., MD, Chief
Joshua D. Brody, DO
James E. Kovacs, DO
Edward Moss, MD
Todd Siegal, MD
Maria S. Solis, MD

SURGERY**Cardiothoracic Surgery**

Vincent E. Lotano, MD
Vincent A. Simonetti, MD

General Surgery

Mark J. Pello, MD, Chief
Umur M. Atabek, MD
Brian R. Kann, MD
Frank C. Koniges, MD
Russell M. Reisner, MD
Robert M. Simons, MD
James Weese, MD

Neurosurgery

H. Warren Goldman, MD, PhD, Chief
Susan R. Hemley, MD
Alan R. Turtz, MD
Steven S. Yocom, DO
James Weinstein, MD

Otolaryngology

Harry Cantrell, MD
Dean A. Drezner, MD

Plastic Surgery and Reconstruction

Martha S. Matthews, MD, Chief

Ann L. Fahey, MD
Christopher J. Salgado, MD

Urology

Raul O. Parra, MD, Chief
Joel L. Marmar, MD

NURSE COORDINATORS**Breast Cancer Center**

Ann Steffney, RN, MSN, OCN

Gastrointestinal Cancer Center

Kay E. Hannigan, RN, BSN, OCN

Genitourinary Cancer Center

Susan Maltman, RN, BSN, OCN

Gynecologic Cancer Center

Wendy Topeka, RN

Leukemia and Lymphoma Center

Alice O’Brien, RN, OCN, HP(ASCP)

Lung Cancer Center

Charu Vora RN, BSN, MSW, BS, OCN

RESEARCH**Basic Research**

Peter Melera, PhD

Clinical Research*HEMATOLOGY–ONCOLOGY*

Robert Somer, MD, Director
Susan Coakley, MHA, CCRP,
Clinical Research Manager

GYNECOLOGIC ONCOLOGY

David Warshal, MD, Director
Mary DeFrancesco, CCRC,
Clinical Research Coordinator

RADIATION ONCOLOGY

Steven DiBiase, MD, Director
Kavita Khatod, MBBS, MA,
Clinical Research Coordinator

SUPPORTIVE SERVICES**Complementary Medicine**

Bonnie Mehr, BA, MT, Manager, Dr. Diane

Barton Complementary Medicine Program

Genetics

Dana Farengo Clark, MS, CGC

Marketing

Tara Elk

Nutritionist

Alicia Michaux, RD

Social Workers

Dawn Marie O’Mara, MSW
Frank Del Rossi, CSW

THE CANCER INSTITUTE OF NEW JERSEY AT COOPER

The Cancer Institute of New Jersey at Cooper is an affiliate of The Cancer Institute of New Jersey, an NCI-designated Comprehensive Cancer Center. It is also the only cancer program in South Jersey designated by the American College of Surgeons as a Teaching Hospital Cancer Program.

The Cancer Institute of New Jersey at Cooper uses a multidisciplinary approach in which medical oncologists, radiation oncologists, gynecologic oncologists and surgeons work together to provide optimal, individualized patient care through six tumor site-specific centers: breast cancer, gastrointestinal cancer, genitourinary cancer, gynecologic cancer, leukemia/lymphoma and lung cancer. Each center offers advanced diagnostics and therapeutics, including access to clinical trials, and has a nurse coordinator to facilitate patient care and education. Supportive care services include personal and nutritional counseling, palliative medicine, support groups, complementary medicine, physical therapy, risk assessment, and genetic testing and counseling, and social work services.

The institute’s Cancer Clinical Trials Center offers more than 100 phase II, III and IV research studies in virtually all types of cancer. Many of these studies are only available in South Jersey—and sometimes the Delaware Valley—at Cooper. Sponsored by the NCI and pharmaceutical companies, these studies cover cancer treatment, cancer prevention, the genetics of cancer, cancer control and supportive care.

Outreach activities to control cancer in New Jersey and Camden County are another component of The Cancer Institute of New Jersey at Cooper. Cooper is the lead organization for the Camden County Cancer Screening Project, which includes the New Jersey Cancer Education and Early Detection (NJ CEED) program that works to increase cancer screenings and resources for underserved populations; the New Jersey Comprehensive Cancer Control Plan, which coordinates and integrates cancer control activities statewide; and the Camden County Cancer Coalition.

Cancer treatment and supportive care services are available in Voorhees, Stratford, Camden and Willingboro N.J.; services vary by location.

For More Information

For more information about The Cancer Institute of New Jersey at Cooper, visit www.coopercancer.org. To schedule an appointment with a Cooper physician, call 1-800-8-COOPER.

- An affiliate of The Cancer Institute of New Jersey, an NCI-designated Comprehensive Cancer Center
- Six multidisciplinary tumor site-specific cancer programs:
 - Breast Cancer Center
 - Gastrointestinal Cancer Center
 - Genitourinary Cancer Center
 - Gynecologic Cancer Center
 - Leukemia/Lymphoma Center
 - Lung Cancer Center
- More than 100 NCI- and industry-sponsored cancer clinical trials each year
- Supportive care services: support groups, complementary medicine, personal and nutritional counseling, physical therapy, and social work services
- Risk assessment and genetic testing and counseling

Services in Voorhees, Stratford, Willingboro and Camden, NJ.

